1718
A. Gopalsamy et al. / Bioorg. Med. Chem. Lett. 10 (2000) 1715±1718
33887. (b) Stilz, H.; Beck, G.; Radau, M. EP 811616. (c) Pitts,
W.; Jadhav, P.K. PCT Int. Appl. WO 99/50249.
References and Notes
1. Seftor, R. E. B.; Seftor, E. A.; Gehlsen, K. R.; Stetler-Ste-
venson, W. G.; Brown, P. D.; Ruoslahti, E.; Hendrix, M. J. C.
Proc. Natl. Acad. Sci. USA 1992, 89, 1557.
2. Montgomery, A. M.P; Reisfeld, R. A.; Cheresh, D. A.
Proc. Natl. Acad. Sci. USA 1994, 91, 8856.
13. Corbett, J. W.; Graciani, N. R.; Mousa, S. A.; DeGrado,
W. F. Bioorg. Med. Chem. Lett. 1997, 7, 1371.
14. Rockwell, A. I.; Rafalski, M.; Pitts, W. J.; Batt, D. G.;
Petraitis, J. J.; DeGrado, W. F.; Mousa, S.; Jadhav, P. K.
Bioorg. Med. Chem. Lett. 1999, 9, 937.
3. Brooks, P. C.; Montgomery, A. M. P.; Rosenfeld, M.;
Reisfeld, R. A.; Hu, T.; Klier, G.; Cheresh, D. A. Cell 1994,
79, 1157.
15. Compound 2 is commercially available from Nova-
Biochem. However, it was readily prepared from a-N-Fmoc-l-
diaminopropionic acid as shown below:
4. Yun, Z.; Menter, D. G.; Nicolson, G. L. Cancer Res. 1996,
56, 3103.
5. Choi, E. T.; Engel, L.; Callow, A. D.; Sun, S.; Trachtenberg,
J.; Santoro, S.; Ryan, U. S. J. Vasc. Surgery 1994, 19, 125.
6. Davies, J.; Warwick, J.; Totty, N.; Philp, R.; Helfrich, M.;
Horton, M. J. Cell. Biol. 1989, 109, 1817.
7. Horton, M. A.; Taylor, M. L.; Arnett, T. R.; Helfrich, M.
H. Exp. Cell Res. 1991, 195, 368.
16. When the reaction was carried out with some unreactive
or sterically hindered chloroformates or isocyanates migration
of the dde protecting group to the a-position leading to the b-
acylation was observed. This was however overcome by using
bulky ddiv following the recent report: Chabra, S. R.; Hothi,
B.; Evans, D. J.; White, P. D.; Bycroft, B. W.; Chan, W. C.
Tetrahedon Lett. 1998, 39, 1603.
8. (a) Engleman, V. W.; Nickols, G. A.; Ross, F. P.; Horton,
M. A.; Griggs, D. W.; Settle, S. L.; Ruminski, P. G.; Tei-
telbaum, S. L. J. Clin. Invest. 1997, 99, 2284. (b) Miller, W. H.;
Bondinell, W. E.; Ku, T. W. F. PCT Int. Appl. WO 98/30542.
(c) Drake, F.H. PCT Int. Appl. WO 98/15278.
9. (a) Lorsbach, B. A.; Kurth, M. J. Chem. Rev. 1999, 99,
1549. (b) Hermkens, P. H. H.; Ottenheijim, H. C. J.; Rees, D.
Tetrahedron 1997, 53, 5643. (c) Hermkens, P. H. H.; Otten-
heijim, H. C. J.; Rees, D. Tetrahedron 1996, 52, 4527. (d)
Booth, S.; Hermkens, P. H. H.; Ottenheijm, H. C. J.; Rees, D.
C. Tetrahedron 1998, 54, 15385. (e) Ellman, J. A. Acc. Chem.
Res. 1996, 29, 132.
10. (a) Duggan, M. E.; Hartman, G. D. PCT Int. Appl. WO
98/18460. (b) Duggan, M. E.; Hartman, G. D.; Homan, W.F.
PCT Int. Appl. WO 98/18461. (c) Hartman, G. D.; Duggan, M.
E. PCT Int. Appl. WO 98/18461. (d) Wehner, V.; Knolle, J.;
Stilz, H. U.; Gadek, T.; McDowell, R. EP 796855. (e) Chan-
drakumar, N.; Clare, M. PCT Int. Appl. WO 97/36861.
11. Ruminski, P. G.; Clare, M.; Collins, P. W. Desai, B. N.;
Lindmark, R. J.; Rico, J. G.; Rogers, T. E.; Russell, M. A.
PCT Int. Appl. WO 97/08145.
17. Acyl resorcinol was chosen as the scaold since the pre-
sence of the -OH group ortho to the carbonyl group forms a
strong H bond (shown by NMR studies) it may obviate 2 of
the hydrating water molecules and improve bioavailability.
18. Isolated yield range 55±88% (5±22 mg) based on loading
as determined by the elemental analysis of resin bound amino
acid 2. All the compounds were puri®ed by reverse-phase
HPLC and further characterized by LC and MS for >90%
purity. LC Conditions: HP 1100, 23 ꢀC, 10mL injected; Col-
umn: YMC-ODS-A 4.6 Â 50 5m Gradient A: 0.05% TFA/
Water, B: 0.05% TFA/Acetonitrile; Time 0 & 1 min: 98%A &
2%B; 7 min: 10%A & 90%B; 8 min: 10%A & 90%B; 8.9 min:
98%A & 2%B; Post time 1 min; Flow rate 2.5 mL/min;
Detection: 215 and 254 nm, DAD.
19. For details on the binding and selectivity assay format see-
Kees, K. L.; Garrick, L. M.; Gopalsamy, A. PCT Int. Appl.
WO 99/52879.
12. (a) Jadhav, P.K.; Smallheer, J. PCT Int. Appl. WO 97/